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creativecommons.org/licenses/by-nc-nd/Abstract Background: Cancer research is among the most active biomedical research do-
mains for the European Union (EU). However, little quantitative empirical evidence is avail-
able to guide the decisions on the choice of disease site to study, specific research domain focus
or allocation of research resources. To inform national/supranational cancer research policy,
high-resolution intelligence is needed.
Methods: We performed a bibliometric analysis of European cancer research papers in the
Web of Science from 2002 to 2013 to quantify research activity in each of the 28 EU Member
States, along with Iceland, Norway and Switzerland (EUR31), which cancer sites/research do-
mains they addressed, and their sources of financial support (2009e2013).
Findings: Cancer research papers from EUR31 correlated well with national Gross Domestic
Products (r2 Z 0.94). However, certain cancer sites (lung, oesophagus and pancreas) were
under-researched relative to their disease burden, whereas central nervous system and blood
cancers were more generously supported than their burden would warrant. An analysis of
research domains indicated a paucity of research on radiotherapy (5%), palliative care
(1.2%) and quality of life (0.5%). European cancer research funding in 2012e2013 amounted
to wV7.6 billion and came from diverse sources, especially in western Europe/Scandinavia,
where in nine countries the charitable sector outspent the government but not in Eastern Eur-
ope where charitable research funding barely exists.
Interpretation: Several countries need to increase their cancer research outputs substantially,
and/or alter their research portfolios to better match their growing (and changing) cancer
burden. More co-ordination among funding agencies is required, so that resources can be@kcl.ac.uk (M. Begum), grant.lewison@kcl.ac.uk (G. Lewison), mark.lawler@qub.ac.uk (M. Lawler),
.
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Cancer research is one of the largest components of
biomedical research in European countries, but aquantitative analysis has been lacking. Many studies
only covered specialist cancer literature [1,2], whereas
we have previously found that more than half of all
cancer papers were published in general medical jour-
nals [3]. Some papers have looked at individual cancer
sites, for example, lung cancer [4] and colorectal cancer
[5] or research domains, for example, palliative care [6]
and surgery [7], and are limited in scope. There is less
information on the funding of cancer research in
Europe, and existing data are now out of date [8].
Cancer research paper outputs can be compared with
the burden of the disease, as measured by disability-
adjusted life years (DALYs), where one DALY corre-
sponds to 1 year of ‘healthy’ life lost [9]. Globally,
cancer accounts for a growing burden (5.1% of DALYs
in 2002; 8.1% in 2012) but it is over-researched relative
to this burden (11.9% of biomedical research in 2002
and 13.2% in 2012). However, in Europe, although the
burden of cancer has increased (16.0% of total causes of
DALYs in 2002, rising to 19.5% in 2012), the level of
cancer-specific biomedical research has remained almost
static (12.1% of biomedical research in 2012 compared
to 11.6% in 2002) (all p < 0.001%), thus rendering
cancer an under-researched disease in Europe. This is
also true in other high-income countries [10].
Data on disease burden were obtained from theWorld
Health Organization (WHO) websites for each of the 28
European Union Member States (EU MS) and for Ice-
land, Norway and Switzerland (EUR31), for the years
2002 and 2012 [9]. Increases in disease burden have
occurred across the EUR31, with the Netherlands having
the highest (2002: 18% and 2012: 23%), Cyprus (8%) the
lowest in 2002, and Bulgaria (15%) the lowest in 2012.
We examined cancer research papers published by the
EUR31 from 2002 to 2013, and their funding from 2009
to 2013. Papers were accessed both from specialist and
from general medical journals and analysed by cancer
anatomical site and research domain. Country Gross
Domestic Product (GDP) data were used to con-
textualise the findings.
2. Methodology
2.1. Outputs of research papers and classification by
subject area
Articles and reviews in the Web of Science (WoSª;
Clarivate Analytics) for the years 2002e2013 and for the
Table 1
List of 31 European countries used to identify cancer research papers.
ISO Country ISO Country ISO Country ISO Country
AT Austria EE Estonia IS Iceland PL Poland
BE Belgium ES Spain IT Italy PT Portugal
BG Bulgaria FI Finland LT Lithuania RO Romania
CH Switzerland FR France LU Luxembourg SE Sweden
CY Cyprus GR Greece LV Latvia SI Slovenia
CZ Czech Rep. HR Croatia MT Malta SK Slovakia
DE Germany HU Hungary NL Netherlands UK United
Kingdom
DK Denmark IE Ireland NO Norway
M. Begum et al. / European Journal of Cancer 100 (2018) 75e84 77EUR31 countries (see International Standards Organi-
zation (ISO) digraph codes, Table 1) were identified
using a complex filter. This included both specialist
journals and title words [3], including the various types
of cancer, genes that increase (or decrease) individuals’
chance of having particular cancers and drug therapies
and other approaches used exclusively for the treatment
of cancer. The filter was originally developed in
consultation with Cancer Research UK and updated by
the Escuela Andaluza de Salud Pu´blica. The filter had a
precision (p, specificity) of 0.95 and recall (r, sensitivity)
of 0.98, so the true number of cancer papers was 0.95/
0.98 Z 0.97 times the apparent number.
Details of the selected papers were downloaded and
combined into a single Excel spreadsheet by means of a
visual basic program (written by Philip Roe, Evalua-
metrics Ltd). Papers were categorised by the fractional
presence of addresses from each of the EUR31 coun-
tries. Because biomedical research outputs strongly
correlate with a country’s wealth [11], fractional cancer
research counts for each EUR31 country were plotted
against its GDP to identify countries that were over-
performing or underperforming relative to their wealth.
Papers were also analysed by cancer site (e.g. breast,
bladder, and so forth) and research domain (e.g.
chemotherapy, surgery, and so forth) using a set of
subfilters (see Tables 2 and 5). Each subfilter consisted
of a set of title words and journal name strings. The
performance of individual countries in each subject area,
relative to the EUR31 as a whole, was calculated.Table 2
List of 23 cancer sites as defined by subfilters with their associated codes, nu
annual average percentage growth (AAPG).
Site Code Papers % Total AAPG
Blood HAE 33,389 11.8 2.4
Breast MAM 29,111 10.3 5.8
Central nervous system CNS 19,438 6.9 4.5
Colon/rectum COL 18,955 6.7 6.8
Lung, trachea, bronchus LUN 13,483 4.8 5.3
Prostate PRO 13,057 4.6 7.4
Head and neck HEN 11,313 4.0 5.0
Stomach STO 10,517 3.7 2.7
Skin SKI 10,309 3.6 3.9
Liver LIV 9886 3.5 5.0
Kidney KID 6713 2.4 5.6
Ovaries OVA 6230 2.2 5.42.2. Research funding
The WoS includes funding information in the
acknowledgement sections of papers as searchable fields
in the Science Citation Index (SCI) since late 2008, so we
confined our analysis to SCI papers from 2009 to 2013
(N Z 135,798). The amount of funding in earlier years
was less than in 2012e2013, so if we assume that the
latter level was more correct, there was an apparent
overall shortfall of 14%. Funding data were corrected to
allow for this and for the calibration factor for the filter
(0.97). The research funding organisations included
those explicitly listed and ones implicit from the paper’s
addresses, but excluded any mentioned in conflict of
interest statements as having paid the authors for un-
related work [12]. We used a double fractionation
method to assign credit. It was assumed that govern-
mental and private non-profit (PNP) funders would only
support researchers in their respective countries but that
international and industrial funders could support
research in any country [13].
A survey of leading researchers in different countries
had previously indicated that the mean cost of a
biomedical research paper in 2013 was approximately
V260,000 [14]. This figure was multiplied by the average
annual contributions for each funding source and cor-
rected for the two shortfalls outlined above to give its
estimated annual contribution.3. Results
3.1. Output of cancer papers
The 282,545 cancer research papers from the EUR31
comprised individual country fractional contributions of
252,718 papers; the difference representing non-
European contributions. EUR31 cancer research pa-
pers increased by 4.3% per annum on a fractional count
basis from 2002 to 2013, but world output increased by
6.5% per annum, mainly because of rapid expansion of
cancer research in East Asia.mbers of papers from 2002 to 2013, percent of all papers (% total) and
Site Code Papers % Total AAPG
Pancreas PAN 5154 1$8 6$6
Sarcoma SAR 5149 1$8 1$9
Cervix CER 4549 1$6 4$4
Bladder BLA 3949 1$4 2$5
Uterus UTE 3440 1$2 4$0
Oesophagus OES 2038 0$7 6$9
Testes TES 1593 0$6 0$8
Eye EYE 685 0$2 0$5
Penis PEN 582 0$2 7$7
Vulva VUL 228 0$1 2$8
Gall bladder GAL 214 0$1 3$2
Table 3
Ratio of observed to expected numbers of papers on the leading 10 cancer sites for the 18 leading European countries, 2002e2013.
Papers HAE MAM CNS COL LUN PRO HEN STO SKI LIV
Papers 252718 29885 25836 17570 17524 12066 11454 10349 9601 9303 8946
DE 45436 1.06 0.75 1.24 0.85 0.79 1.06 0.98 1.19 1.12 1.20
IT 37876 1.13 0.92 1.09 0.93 1.25 0.89 1.21 1.03 1.04 1.38
UK 37541 0.90 1.19 0.76 1.15 0.82 1.10 0.95 0.77 0.85 0.66
FR 30127 1.06 0.92 1.07 0.89 1.13 1.00 0.76 0.92 0.89 1.28
NL 16068 0.84 1.09 0.77 1.32 1.13 1.10 1.18 1.03 0.99 0.79
ES 15654 1.05 0.99 1.06 1.10 1.17 0.78 1.09 0.97 0.95 1.12
SE 9205 0.94 1.17 0.96 1.14 0.68 1.61 0.62 0.83 0.85 0.53
PL 7543 1.04 1.01 1.06 0.92 1.08 0.47 1.01 1.16 1.06 0.56
GR 7243 1.03 1.23 0.74 1.06 1.49 0.82 1.23 1.40 0.67 0.87
CH 6837 1.00 0.84 1.19 0.73 1.09 0.90 1.08 0.65 1.38 0.98
BE 6253 0.85 1.11 1.02 0.74 1.24 0.98 1.01 0.97 0.94 1.08
AT 5563 1.18 1.00 0.98 0.75 0.69 1.27 0.99 0.66 1.39 1.06
DK 4713 0.92 1.41 0.67 1.48 1.04 0.69 0.78 0.75 1.16 0.39
NO 4054 0.81 1.31 0.93 1.41 0.89 1.07 0.67 0.87 0.93 0.45
FI 3721 0.66 1.48 0.80 0.94 0.73 1.96 1.39 1.09 0.91 0.35
CZ 3005 1.52 0.66 1.21 1.00 0.62 0.61 0.70 0.80 0.84 0.93
IE 2247 0.56 1.59 0.61 1.35 0.98 1.36 0.83 1.08 0.75 0.45
PT 2079 0.57 1.38 0.72 0.85 0.87 0.92 1.59 2.22 0.75 0.53
Countries (based on fractional counts) and sites (based on integer counts) are ranked by total research papers. Contributions by non-European
countries are not included. Values > 2 shaded blue; values > 1.41 shaded green; values < 0.71 shaded yellow; values < 0.5 shaded pink. See
Table 1 for country ISO codes and Table 2 for cancer site codes. See Tables 9 and 10 in Appendix for data on all 31 European countries.
Table 4
Percentage of cancer papers that received funding by cancer site,
2009e2013.
Site N Mean % Funded Site N Mean % Funded
HAE 15,035 2.79 69.1 TES 631 1.63 54.7
MAM 14,260 2.68 68.2 SAR 2287 1.99 51.6
SKI 4887 2.22 62.4 STO 4679 1.77 51.1
EYE 271 2.28 61.6 BLA 1760 1.56 47.8
COL 9572 2.07 60.7 KID 3304 1.48 47.6
LUN 6614 2.05 59.2 UTE 1661 1.69 47.4
PRO 6673 2.12 59.1 OES 1001 1.47 45.3
CNS 9439 2.08 58.7 HEN 5475 1.33 44.4
OVA 3056 2.68 58.6 GAL 84 1$04 31.0
PAN 2637 2.42 56.8 PEN 295 0$81 30.2
CER 2124 1.74 56.3 VUL 106 0$73 26.4
LIV 4816 1.86 55.4
N, number of papers; mean, mean number of funders per paper and %
Funded, percentage of papers with explicit or implicit funding ac-
knowledgements. Sites ordered by % Funded. See Table 2 for cancer
site codes.
M. Begum et al. / European Journal of Cancer 100 (2018) 75e8478The amount of cancer research from each of the
EUR31 countries correlated strongly with GDP
(r2 Z 0.94), see Fig. 1. Almost all noticeable departures
from the correlation line were statistically significant
with p < 0.001%. Luxembourg, Latvia and Cyprus
showed the lowest outputs of cancer research papers
relative to their GDP (red-coloured ISO codes). How-
ever, they were also among the countries with the fastest
annual average percentage growth (AAPG): Cyprus
18%, Lithuania 16% and Luxembourg 15%. Romania
contributed to very few papers relative to its GDP but
showed the fastest expansion of its output (36% per
annum). The countries with the highest outputs, with
twice the expected number of papers, were Slovenia,
Croatia, Iceland and Greece (green-coloured ISO
codes), all of which increased their annual outputs
(AAPG: 11%, 10%, 4% and 4% respectively). Scandi-
navian countries, except Denmark, showed some of the
Table 5
List of 12 research domains as defined by subfilters with their associ-
ated codes, numbers of papers from 2002 to 2013, percent of all papers
(% total) and annual average percentage growth (AAPG).
Research domain Code Papers % Total AAPG
Genetics GENE 55,873 19.8 2.3
Prognosis PROG 30,479 10.8 8.8
Surgery SURG 28,336 10.0 6.0
Standard chemotherapy CHEM 23,601 8.4 2.1
Pathology PATH 23,174 8.2 3.4
Radiotherapy RADI 15,103 5.3 6.2
Epidemiology EPID 14,766 5.2 8.1
Diagnosis DIAG 12,213 4.3 6.8
Targeted chemotherapy TARG 7156 2.5 18.7
Screening SCRE 5392 1.9 7.0
Palliative care PALL 3413 1.2 9.6
Quality of life QUAL 1540 0.5 12.6
M. Begum et al. / European Journal of Cancer 100 (2018) 75e84 79lowest levels of growth in their cancer research, with
Finland having no growth over the 12-year period.
The amount of international collaboration in cancer
research for the European countries tended to vary
inversely with their output (Fig. 2). International collab-
oration is much higher in ‘western’ European countries,
especially Nordic countries and Switzerland, than in
‘eastern’ countries, with Croatia, the most recent EU
member, showing the least international collaboration.
This difference may reflect the shorter time that ‘acces-
sion’ Member States in the east have been the EU MS.Fig. 1. Plot of cancer (ONCOL) paper output on a fractional
count basis, 2002e2013, against GDP (2007e2008) in billion US
dollars for European countries. MT was omitted as output and
GDP is too small, and graph is on a logelog scale. Dashed lines
show values 2 or 0.5 relative to least-squares correlation line.
See Table 1 for country ISO codes.3.2. Research output by cancer sites
A majority (68%) of cancer papers from 2002 to 2013
could be classified into one or more of the 23 cancer sites
(Table 2). Cancers of the blood and breast received the
most attention, but pancreatic and oesophageal cancers
had much smaller outputs, as did several female cancers
(ovaries, cervix, uterus and vulva). Fig. 3 indicates a
rather weak correlation between the disease burden from
the different cancers and the amount of research per-
formed, with the central nervous system appearing over-
researched in 2011e2013 (expected output 3129,
observed output 5887; p < 0.001 on Poisson distribution
with one degree of freedom) and lung cancer significantly
under-researched (expected output 18,262, observed
output 4271, p< 0.001%). The arrows from the red spots
to the green spots quantify changes from the beginning to
the end of the study period. These data also reveal the
relative paucity of research in 2011e2013 on oesophageal
(expected output 2247, observed output 640, p< 0.001%)
and pancreatic (expected output 4809, observed output
1634, p < 0.001%) cancers. The burden of pancreatic
cancer has increased by more than a third between 2000
and 2010 (from 1406 to 1723 k DALYs, p < 0.001%).
Table 3 shows the research performance of the lead-
ing 18 European countries on the top 10 cancer sites (see
Appendix for data on all countries and sites). If the
shortfalls in papers for particular cancers, such as those
of the lung, pancreas and oesophagus, are to be rectified,
then greater collaboration will be needed with countries
with a strong commitment to relevant research on these
cancer sites. For example, Germany is very active in
both pancreatic (1425 papers, 1.73-fold higher) and
oesophageal (465 papers, 1.44-fold higher) cancers, so
more collaboration with other EUR31 countries could
be beneficial.
Analysis of funding for the EUR31 countries in
2009e2013 showed that 59% of the 119,753 papers had
one or more explicit or implicit funding acknowledge-
ments that vary by cancer site (see Table 4). The three
sites identified previously as requiring greater research
attention (lung, oesophagus and pancreas) all received
the same or lower levels of funding than this average (for
pancreatic cancer, p w 0.02; for oesophageal cancer,
p < 0.001).
3.3. Cancer research output by research domain
Research domain was identified for 59% of papers
evaluated (see Table 5). Genetics was the dominant
research domain, followed by prognosis and surgery.
There was very little research on quality of life, palliative
care or screening, although these domains have been
expanding their outputs rapidly. Standard chemo-
therapy showed the slowest growth rate, whereas tar-
geted chemotherapy showed the fastest annual growth
in output.
Fig. 2. Percentages of international collaboration in cancer research (ONCOL), 2002e2013, by European countries plotted against their
output (fractional counts of papers). Abscissa is on a log scale. See Table 1 for country ISO codes.
M. Begum et al. / European Journal of Cancer 100 (2018) 75e8480Commitment of the 18 leading European countries to
different research domains is shown in Table 6. In the
three neglected research domains (quality of life, palli-
ative care and screening), the Scandinavian countries
performed well, as did the UK and the Netherlands.
However, most of the large countries (France, Germany,
Italy, Poland and Spain) relatively underperformed in
these domains.Fig. 3. Scatterplot of European cancer research paper outputs on
different cancer sites, 2002e2004 and 2011e2013, as a percentage
of the total European burden of cancer as measured by disability-
adjusted life years (DALYs) from the different cancer sites,
logelog plot. Red and green dots indicate the beginning and end
of the study period, respectively. See Table 2 for cancer site codes.Table 7 shows the amount of funding for papers in
each research domain. Radiotherapy (49%) and surgery
(30%) received much less funding than chemotherapy
(67%) and targeted chemotherapy (73%). For all four
treatment modalities, the differences from the mean
funding level of 59% were significant with p < 0.001%.
3.4. Sources of research funding
In 2013, the fractional European output was 29,254
research papers, and at an average cost of V260,000, the
estimated public domain cancer research expenditure
resulting in a published paper in Europe was V7.6
billion.
Fig. 4 shows the amount of funding from each sector
for 18 leading countries. Government supported the
largest share of European cancer research (30%), followed
by the PNP (19%), industrial (7%) and international sec-
tors (3%). The European Commission was the largest
single funder of European cancer research, with 2836
papers (2.4% of the total), amounting to approximately
V147 million spent, with the number of research papers
receiving its support increasing by 16% per annum.
Funding from government, including departments,
agencies and local authorities, ranged from 63% in
Estonia to 7% in Greece. In nine countries in Western
Europe, PNP funders outspent the public sector,
notably in Scandinavia (data for Iceland not shown) and
the UK. Collecting charities formed the largest PNP
group, supporting 10% of all cancer research, but more
Table 6
Ratio of observed to expected numbers of papers in 12 research domains for the leading 18 European countries, 2002e2013, with >2000 papers.
Papers GENE PROG SURG CHEM PATH RADI EPID DIAG TARG SCRE PALL QUAL
Papers 252718 48258 27188 26584 21480 20715 13939 12296 11333 6200 4840 3151 1409
DE 45436 1.03 0.94 1.09 0.88 1.06 1.10 0.69 1.12 1.02 0.75 0.70 0.83
IT 37876 0.86 0.94 1.17 1.27 0.97 0.75 0.88 0.93 1.36 0.81 0.84 0.49
UK 37541 0.96 1.02 1.03 0.85 0.92 0.95 1.11 0.92 0.80 1.26 1.62 1.49
FR 30127 0.85 0.92 1.06 1.15 0.85 1.17 0.94 0.92 1.14 0.82 0.65 0.59
NL 16068 0.97 1.13 1.07 1.03 0.97 1.70 1.25 1.03 0.78 1.80 1.32 2.28
ES 15654 1.12 1.05 0.75 1.00 1.14 0.62 0.91 1.11 1.15 0.92 0.89 0.75
SE 9205 1.31 1.31 0.67 0.78 0.80 1.00 2.29 0.90 0.61 1.26 1.78 1.88
PL 7543 1.28 0.73 0.74 0.97 0.95 0.81 0.95 1.00 0.70 0.42 0.74 0.62
GR 7243 0.99 1.01 1.08 1.51 1.07 0.68 0.77 0.97 0.99 1.12 0.94 0.87
CH 6837 0.86 0.91 0.92 0.95 1.07 1.21 0.64 1.27 1.23 0.65 0.74 0.60
BE 6253 0.76 0.81 0.95 1.06 0.86 1.43 0.54 0.79 1.22 1.16 0.74 0.53
AT 5563 1.01 1.06 0.99 1.05 1.14 1.04 0.62 1.20 1.37 0.83 0.48 0.40
DK 4713 1.07 1.39 0.69 0.80 0.94 1.40 2.59 1.08 0.70 1.48 1.78 2.02
NO 4054 1.21 1.53 0.74 0.63 1.19 1.14 1.68 0.89 0.44 1.69 2.80 3.05
FI 3721 1.51 1.51 0.61 0.65 1.19 0.63 1.81 0.83 0.67 1.98 0.75 1.04
CZ 3005 1.34 0.83 0.83 1.24 1.07 0.71 0.86 0.82 1.01 0.49 0.27 0.33
IE 2247 0.96 1.10 1.37 0.67 1.06 0.69 0.58 1.03 0.81 1.30 1.01 1.04
PT 2079 1.43 0.81 0.41 0.74 1.48 0.35 1.24 1.13 0.65 0.85 0.63 0.97
Countries (based on fractional counts) and research domains (based on integer counts) ranked by number of papers. Values > 2 shaded blue;
values > 1.41 shaded green; values < 0.71 shaded yellow; values < 0.5 shaded pink. See Table 1 for country ISO codes and Table 5 for research
domain codes.
M. Begum et al. / European Journal of Cancer 100 (2018) 75e84 81in Sweden (23%), the UK, Iceland (both 22%) and
Denmark (20%). Endowed foundations supported 3787
papers (3.2%), with some countries receiving signifi-
cantly more than the EUR31 average, namely Denmark
(17%), Finland (12%) and Sweden (9%) (all p < 0.001%).
Their individual contributions were mostly small, but
their huge number meant that their collective support
was important, particularly in Germany (892 papers)
and Italy (639), the latter mostly from banking foun-
dations. In Eastern Europe, the PNP sector was almost
non-existent.
Industrial companies supported 6.6% of all European
cancer research, with significantly more funding inTable 7
Percentage of cancer papers that received funding by research domain,
2009e2013.
Research
domain
N Mean %
Funded
Research
domain
N Mean %
Funded
GENE 24,815 3.41 79.2 QUAL 851 1.59 64.3
EPID 7661 4.38 76.2 PALL 1803 1.40 59.4
TARG 4636 2.56 72.7 PATH 10,756 1.82 56.1
CHEM 10,518 2.14 67.2 RADI 7658 1.25 49.2
SCRE 2680 2.11 65.0 DIAG 6207 1.48 48.0
PROG 16,512 2.51 64.6 SURG 14,163 0.73 30.5
Mean, mean number of funders per paper; N, number of papers and %
Funded, percentage of papers with explicit/implicit funding acknowl-
edgements. See Table 5 for domain codes.Switzerland (13%) and Germany (10%) (for both,
p < 0.001%). Industry-funded support went largely to
Germany (2042 research papers) and the UK (1187
research papers). Very little support went to the 13
accession countries of Eastern Europe (348 research
papers in total).
The French National Health and Medical Research
Institute (INSERM) and the Italian Ministry of Health
were the leading government bodies to support research,
contributing to the equivalent of 2800 (estimated atFig. 4. Percentages of cancer research funding by sector,
2009e2013, for the leading 18 countries (fractional counts >1000
papers and integer counts >1500 papers). NONE, no acknowl-
edged funding; INTL, international; INDY, industry; PNP, pri-
vate non-profit; GOV, government. See Table 1 for country ISO
codes.
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over the 5-year period, seeTable 8 in theAppendix. Cancer
Research UK was by far the largest of the collecting
charities (2004 research papers, V115m/year). The two
leading industrial funders were Novartis AG (546 papers)
and Hoffmann-La Roche SA (529 papers). Based on their
support for published papers, we estimate that they each
spent in excess of V30 million per annum in Europe.
Of the four treatment approaches evaluated, targeted
chemotherapy papers received 23% of their support
from industry, compared with standard chemotherapy
(14%) (both above the European average), radiotherapy
(6.1%) and surgery (3.0%) (p < 0.001). Some 37% of the
papers did not acknowledge any funding sources and
probably were supported by the university and/or hos-
pital in which the research was conducted.4. Discussion and conclusions
Cancer research is a critical component of a country’s
performance in providing optimal cancer care for its cit-
izens [15,16]. Our research reveals that certain European
countries are underperforming in cancer research relative
to their GDP and need to do more to address the rising
burden of cancer. They may also need to change their
research emphasis/prioritisation to respond to the chal-
lenges posed by neglected cancer sites or research do-
mains. This will be challenging given the multiplicity of
funding sources. Umbrella organisations such as the
(British) Association of Medical Research Charities,
which do not appear to exist elsewhere in the EU, offer a
possible solution. [In Ireland, there is the Medical
Research Charities Group, but many of its members do
not actually support research.] They can provide
comprehensive information on their members’ research
expenditure, ensure that peer review is used in grant
allocation, and lobby for better conditions for research,
such as fiscal benefits for collecting charities. Research or
disease-specific organisations can also help to co-ordinate
research funding and identify and fund research gaps (as
Breast Cancer Campaign has done for breast cancer [17],
and Bowel Cancer UK has just published for colorectal
cancer research prioritisation [18]). Investigating the po-
tential for short international exchange visits to spread
good practice may also help individual MS to benefit
from expertise elsewhere in Europe.
There is a particular need to encourage charitable and
philanthropic funding in Eastern Europe, where cancer
research support comes almost entirely from central
government. Recent data from the Charities Aid
Foundation [19] ranked the Eastern European MS very
low for charitable giving, whereas the older MS (and
particularly the Scandinavian ones) fared much better.
However, there is no lack of cancer research in all the
accession MS: Croatia and Slovenia are clearly per-
forming at a strong level (Fig. 1). Greater internationalcollaboration may help (see Fig. 2), e.g. through tar-
geted collaborative funding mechanisms.
Despite large financial support from the PNP sector,
the UK’s research outputs are low relative to its GDP
(Fig. 1), and cancer survival rates in the UK are
among the lowest in Western Europe [20]. Because
treatment in institutions heavily involved in research is
strongly associated with better outcomes for cancer
patients, including postoperative mortality and 5-year
survival [21], more cancer research in the UK is likely to
lead to improved survival rates. Moreover, greater
government and PNP support may stimulate additional
industrial support [22].
An important finding of our study is the lack of
research on three particular cancer sitesdlung, oeso-
phageal and pancreaticdwhose burden is increasing and
whose prognosis is usually poor [23]. Given the challenges
related to early diagnosis in these cancers, there is a need
to identify biomarkers and better screening tools, with
more research funding directed to these cancer sites. For
example, only 1.7% of lung cancer research papers
focussed on screening, and fewer for oesophageal (0.59%)
and pancreatic (0.33%) cancers, whereas screening ac-
counts for 8% of breast cancer papers (p < 0.001%).
The European research portfolio also needs to
include more activity in surgery [24] and radiotherapy
[25], given their significant role in cancer cure and con-
trol. Research in these domains is poorly funded, which
may reflect the erroneous public perception, reinforced
by media stories [26,27] that chemotherapy, which is
well funded, is the main way through which cancers are
cured. We also found a movement from funding of
standard chemotherapy towards more targeted chemo-
therapy/biological therapy approaches.
Critically, there is a lack of research on quality of life
and palliative care, especially in Eastern and Southern
Europe (except for Cyprus). This may both reflect and
contribute to barriers to effective palliative care across
Eastern Europe [28]. A greater focus on and investment
in these areas is needed [29]. On the other hand, there
appears to be a substantial support for two basic
research domains, namely genetics and epidemiology.
While these areas are undoubtedly important, this focus
may also reflect the amount of publicity given to these
domains in media stories [26,27].
This study has certain limitations. The filter only
covers papers that are overtly concerned with cancer, so
basic biology may be under-represented. However,
many cancer charities devote substantial resources to
this type of research. For example, Cancer Research UK
devoted 37% of their annual research activity to the
biology of cancer in 2010 [30]. Second, the quality and
impact of the research were not addressed here but will
be examined in a subsequent paper. Third, the coding of
research funding organisations is a complex activity that
is constantly evolving [13]. Fourth, we had to assume
that financial contributions to a country on each paper
M. Begum et al. / European Journal of Cancer 100 (2018) 75e84 83were equal, but this will often not be the case. Larger
funders will probably give bigger grants, or multiple
ones, and so our estimates of their support may be too
low. Thus, our estimate of the funding from Cancer
Research UK is much less than the expenditure in their
annual reports [13]. In contrast, we will have over-
estimated contributions by the smaller funders. This is
a problem inherent with funding analysis. Finally, many
papers have no explicit or implicit funding but are likely
to have received support from their university or health
service. This has not been addressed.
Notwithstanding these caveats, we have reached
evidence-informed conclusions that we consider to be
robust. The analysis of research papers from both
specialist cancer journals and general medical journals
provides a more comprehensive picture of European
cancer research activity than has previously been
attempted. Results have been contextualised with data
on cancer burden and with the GDP for different Eu-
ropean countries. These data can help support more
policy-focussed cancer research agenda for individual
European governments. Such agenda would be partic-
ularly relevant to those EU MS that perform low levels
of cancer research or require a better alignment between
country-specific cancer challenges and research prior-
ities. We have identified certain research gaps in indi-
vidual countries, both for cancer sites and specific
research domains. Addressing these research and fund-
ing gaps through a more EUR31-wide focussed collab-
orative approach can help to ensure better cancer
control and care for European citizens.
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